Purity isn’t a claim.
It’s a co-crystal.

Co-crystallisation pairs a cannabinoid with a co-former molecule to create a new crystal structure, recognised by the FDA as a novel entity.

The result is a stable, solid-form ingredient suited to pharmaceutical-grade dosing, with none of the degradation issues that limit conventional cannabinoid formats.